MDCO - The Medicines Company

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
36.40
+0.56 (+1.56%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close35.84
Open35.58
Bid0.00 x 1300
Ask38.00 x 900
Day's Range35.03 - 37.16
52 Week Range16.69 - 41.57
Volume3,900,259
Avg. Volume1,215,266
Market Cap2.69B
Beta (3Y Monthly)2.18
PE Ratio (TTM)N/A
EPS (TTM)-2.88
Earnings DateJul 30, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est57.36
Trade prices are not sourced from all markets
  • Alnylam Completes Enrollment in Phase III Study of Lumasiran
    Zacks6 days ago

    Alnylam Completes Enrollment in Phase III Study of Lumasiran

    Alnylam (ALNY) completes enrollment in its ILLUMINATE-A phase III study on lumasiran for the treatment of adults and children with primary hyperoxaluria type 1.

  • Markit6 days ago

    See what the IHS Markit Score report has to say about Medicines Co.

    Medicines Co NASDAQ/NGS:MDCOView full report here! Summary * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for MDCO with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MDCO. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold MDCO had net inflows of $2.46 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Did Hedge Funds Drop The Ball On Medicines Company (MDCO)?
    Insider Monkey7 days ago

    Did Hedge Funds Drop The Ball On Medicines Company (MDCO)?

    Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]

  • Signal Says This Drug Stock Isn't Done Climbing
    Schaeffer's Investment Research11 days ago

    Signal Says This Drug Stock Isn't Done Climbing

    The Medicines Company has nearly doubled in 2019

  • Alnylam Completes Rolling NDA Submission to FDA for Givosiran
    Zacks18 days ago

    Alnylam Completes Rolling NDA Submission to FDA for Givosiran

    Alnylam (ALNY) completes the rolling NDA submission to the FDA for givosiran, which is being evaluated for the treatment of acute hepatic porphyria.

  • Benzinga20 days ago

    These Bullish Medicines Company Options Trades Suggest More Upside Could Be Coming

    The Medicines Company (NASDAQ: MDCO ) shares traded higher by 2.5 percent on Tuesday and are now up 7.5 percent overall in the past week. At this point, Medicines Company traders are likely considering ...

  • Options Traders Expect Huge Moves in Medicines Company (MDCO) Stock
    Zacks20 days ago

    Options Traders Expect Huge Moves in Medicines Company (MDCO) Stock

    Investors need to pay close attention to Medicines Company (MDCO) stock based on the movements in the options market lately.

  • Alnylam Initiates Phase I Study on Hypertension Candidate
    Zacks21 days ago

    Alnylam Initiates Phase I Study on Hypertension Candidate

    Alnylam (ALNY) initiates phase I study on ALN-AGT, an investigational RNAi therapeutic targeting angiotensinogen for the treatment of hypertension in high unmet need populations.

  • Benzinga21 days ago

    Notable Insider Buys This Past Week: Coty, Zillow and More

    Conventional wisdom says that insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. Zillow Group Inc (NASDAQ: Z) had a director return for more notable indirect share purchases this past week. Zillow's new business in buying and selling homes has helped boost its revenue.

  • Business Wire28 days ago

    The Medicines Company Presents Clinical Data Analyses for Inclisiran at 87th European Atherosclerosis Society Congress

    A combined analysis (N=279) from the Phase 2 ORION-1 and Phase 1 ORION-7 trials, presented during an e-poster session, demonstrated that patients across a range of renal function levels achieved consistent reductions in low-density lipoprotein cholesterol (LDL-C) with no dose adjustment necessary for patients with renal impairment. Results from the Phase 2 ORION-2 pilot study, presented as a late-breaking abstract, showed that inclisiran provided durable reductions in LDL-C levels up to day 180 in patients with homozygous familial hypercholesterolemia (HoFH), a genetic disorder characterized by very high levels of LDL-C and early onset of cardiovascular disease, without the need to increase the dose of inclisiran.

  • Medicines Co. (MDCO) Up 17.1% Since Last Earnings Report: Can It Continue?
    Zackslast month

    Medicines Co. (MDCO) Up 17.1% Since Last Earnings Report: Can It Continue?

    Medicines Co. (MDCO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Benzingalast month

    Medicines Company Rallies On Positive LDL Cholesterol Study Results

    Medicines Company announced interim results Saturday from the ongoing Phase 2 ORION-3 study that is evaluating the efficacy, safety and tolerability of inclisiran 300 mg in patients with atherosclerotic cardiovascular disease and elevated LDL cholesterol. The results show a consistent lowering of LDL cholesterol by more than 50 percent, with an overall follow-up of up to three years. The results were presented as a late-breaking presentation at the National Lipid Association Scientific Sessions in Miami.

  • PR Newswirelast month

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating The Medicines Company for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK, May 20, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of The Medicines Company (MDCO). You may also contact Robert H. Lefkowitz, Esq. Purcell Julie & Lefkowitz LLP is a law firm exclusively committed to representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty and other types of corporate misconduct.

  • Business Wirelast month

    New Long-Term Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol with No Material Safety Observations Out to Three Years

    The Medicines Company (MDCO) today announced interim results from the ongoing ORION-3 open-label extension study (Group 1, n=290) which showed that twice-a-year dosing with inclisiran sodium 300 mg resulted in consistent lowering of low density lipoprotein cholesterol (LDL-C) by more than 50 percent with overall follow-up of up to three years. Inclisiran was well tolerated, and no material safety issues were observed in the study.

  • What Kind Of Share Price Volatility Should You Expect For The Medicines Company (NASDAQ:MDCO)?
    Simply Wall St.last month

    What Kind Of Share Price Volatility Should You Expect For The Medicines Company (NASDAQ:MDCO)?

    Anyone researching The Medicines Company (NASDAQ:MDCO) might want to consider the historical volatility of the share...

  • Benzingalast month

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

    Biotech stocks saw a reversal in sentiment as the week saw an earnings deluge from small-, micro- and nano-cap biotechs and some M&A activity . Here are some key catalysts for the unfolding week that should ...

  • Business Wirelast month

    The Medicines Company to Host Investor Conference Call and Webcast During National Lipid Association’s 2019 Scientific Sessions

    The Medicines Company (MDCO) will host a conference call and webcast for investors on Saturday, May 18, 2019, at 5:30 p.m. EDT. During the call, the Company’s management and clinical trial investigators will review interim results on the long-term safety and efficacy data of inclisiran from the ongoing ORION-3 study.

  • Business Wire2 months ago

    The Medicines Company to Participate in the Bank of America Merrill Lynch 2019 Healthcare Conference

    The Medicines Company announced that it will participate in the Bank of America Merrill Lynch 2019 Healthcare Conference on Tuesday, May 14, 2019, in Las Vegas. The Company is scheduled to present at 8:00 a.m.

  • Did Hedge Funds Drop The Ball On The Medicines Company (MDCO) ?
    Insider Monkey2 months ago

    Did Hedge Funds Drop The Ball On The Medicines Company (MDCO) ?

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

  • Alnylam (ALNY) Reports Narrower-Than-Expected Loss in Q1
    Zacks2 months ago

    Alnylam (ALNY) Reports Narrower-Than-Expected Loss in Q1

    Alnylam (ALNY) reports narrower-than-expected loss in the first quarter of 2019. Also, sales beat estimates.